Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon Colomer

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
International Journal of Oncology|December 22, 2007
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of schedulingCristina Oliveras-Ferraros, Alejandro Vazquez-Martin, Ramon Colomer, et al.
International Journal of Molecular Medicine|June 6, 2007
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)Laura Ferrer-Soler, Alejandro Vazquez-Martin, Joan Brunet, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 6, 2004
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cellsJavier A Menendez, Luciano Vellon, Inderjit Mehmi, et al.
Molecular Carcinogenesis|July 11, 2007
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancerJoan Brunet, Alejandro Vazquez-Martin, Ramon Colomer, et al.
Oncology|January 17, 2024
Is Older Age an Independent Prognostic Factor of Survival in Metastatic Colorectal Cancer?Patricia Toquero, Rebeca Mondéjar, Nuria Romero-Laorden, et al.
Breast Cancer Research : BCR|May 26, 2019
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibitionMiguel Quintela-Fandino, Juan V Apala, Diego Malon, et al.
Peptides|August 17, 2010
Antimicrobial cyclic decapeptides with anticancer activityLidia Feliu, Glòria Oliveras, Anna D Cirac, et al.
Cancers|June 24, 2022
The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA RepairVilma Pacheco-Barcia, Andrés Muñoz, Elena Castro, et al.
Breast Cancer Research and Treatment|June 13, 2002
Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cellsJavier Abel Menéndez, Santiago Ropero, Maria Mar del Barbacid, et al.
Oncotarget|March 7, 2015
Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancerBegoña Martin-Castillo, Eugeni Lopez-Bonet, Maria Buxó, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
International Journal of Oncology|December 22, 2007
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of schedulingCristina Oliveras-Ferraros, Alejandro Vazquez-Martin, Ramon Colomer, et al.
International Journal of Molecular Medicine|June 6, 2007
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)Laura Ferrer-Soler, Alejandro Vazquez-Martin, Joan Brunet, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 6, 2004
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cellsJavier A Menendez, Luciano Vellon, Inderjit Mehmi, et al.
Molecular Carcinogenesis|July 11, 2007
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancerJoan Brunet, Alejandro Vazquez-Martin, Ramon Colomer, et al.
Oncology|January 17, 2024
Is Older Age an Independent Prognostic Factor of Survival in Metastatic Colorectal Cancer?Patricia Toquero, Rebeca Mondéjar, Nuria Romero-Laorden, et al.
Breast Cancer Research : BCR|May 26, 2019
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibitionMiguel Quintela-Fandino, Juan V Apala, Diego Malon, et al.
Peptides|August 17, 2010
Antimicrobial cyclic decapeptides with anticancer activityLidia Feliu, Glòria Oliveras, Anna D Cirac, et al.
Cancers|June 24, 2022
The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA RepairVilma Pacheco-Barcia, Andrés Muñoz, Elena Castro, et al.
Breast Cancer Research and Treatment|June 13, 2002
Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cellsJavier Abel Menéndez, Santiago Ropero, Maria Mar del Barbacid, et al.
Oncotarget|March 7, 2015
Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancerBegoña Martin-Castillo, Eugeni Lopez-Bonet, Maria Buxó, et al.
Pageof 8